[{"address1": "500 North Beacon Street", "address2": "4th Floor", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "857 285 5300", "website": "https://www.kymeratx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 225, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bruce L. Booth DPHIL, Ph.D.", "age": 51, "title": "Co-Founder & Independent Chairman", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 70000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nello  Mainolfi M.D., Ph.D.", "age": 47, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 1226500, "exercisedValue": 1110312, "unexercisedValue": 37845672}, {"maxAge": 1, "name": "Mr. Bruce N. Jacobs CFA", "title": "Chief Financial Officer", "fiscalYear": 2024, "totalPay": 754540, "exercisedValue": 703665, "unexercisedValue": 9900757}, {"maxAge": 1, "name": "Dr. Jeremy G. Chadwick Ph.D.", "age": 62, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 719400, "exercisedValue": 0, "unexercisedValue": 838368}, {"maxAge": 1, "name": "Dr. Jared A. Gollob M.D.", "age": 61, "title": "Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 768400, "exercisedValue": 3280617, "unexercisedValue": 6586792}, {"maxAge": 1, "name": "Ms. Justine E. Koenigsberg", "title": "Vice President of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian R. Adams J.D.", "age": 51, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen  Weisbach", "title": "Head of People & Culture", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juliet  Williams B.A Ph.D.", "title": "Head of Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Noah  Goodman M.B.A.", "age": 38, "title": "Chief Business Officer", "yearBorn": 1987, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1769904000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 86.5, "open": 85.87, "dayLow": 85.6, "dayHigh": 89.28, "regularMarketPreviousClose": 86.5, "regularMarketOpen": 85.87, "regularMarketDayLow": 85.6, "regularMarketDayHigh": 89.28, "payoutRatio": 0.0, "beta": 2.256, "forwardPE": -23.989965, "volume": 1030699, "regularMarketVolume": 1030699, "averageVolume": 983401, "averageVolume10days": 835360, "averageDailyVolume10Day": 835360, "bid": 63.76, "ask": 110.08, "bidSize": 2, "askSize": 2, "marketCap": 6991915008, "fiftyTwoWeekLow": 19.445, "fiftyTwoWeekHigh": 103.0, "allTimeHigh": 103.0, "allTimeLow": 9.6, "priceToSalesTrailing12Months": 159.87001, "fiftyDayAverage": 77.5098, "twoHundredDayAverage": 55.267475, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 5866659840, "profitMargins": 0.0, "floatShares": 47466212, "sharesOutstanding": 79999027, "sharesShort": 9356012, "sharesShortPriorMonth": 7938651, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.117, "heldPercentInsiders": 0.02257, "heldPercentInstitutions": 1.13033, "shortRatio": 12.61, "shortPercentOfFloat": 0.1408, "impliedSharesOutstanding": 79999028, "bookValue": 13.19, "priceToBook": 6.626232, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -295121984, "trailingEps": -3.6, "forwardEps": -3.64319, "enterpriseToRevenue": 134.141, "enterpriseToEbitda": -18.246, "52WeekChange": 1.2176137, "SandP52WeekChange": 0.11527538, "quoteType": "EQUITY", "currentPrice": 87.4, "targetHighPrice": 138.0, "targetLowPrice": 90.0, "targetMeanPrice": 116.71429, "targetMedianPrice": 118.0, "recommendationMean": 1.30435, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 21, "totalCash": 505681984, "totalCashPerShare": 7.028, "ebitda": -321535008, "totalDebt": 83997000, "quickRatio": 7.065, "currentRatio": 7.381, "totalRevenue": 43735000, "debtToEquity": 8.877, "revenuePerShare": 0.533, "returnOnAssets": -0.19209999, "returnOnEquity": -0.32092997, "grossProfits": -260819008, "freeCashflow": -139944752, "operatingCashflow": -227928000, "revenueGrowth": -0.261, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -32.07887, "financialCurrency": "USD", "symbol": "KYMR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 1.04046, "regularMarketPrice": 87.4, "shortName": "Kymera Therapeutics, Inc.", "longName": "Kymera Therapeutics, Inc.", "corporateActions": [], "fiftyTwoWeekLowChange": 67.955, "fiftyTwoWeekLowChangePercent": 3.4947288, "fiftyTwoWeekRange": "19.445 - 103.0", "fiftyTwoWeekHighChange": -15.599998, "fiftyTwoWeekHighChangePercent": -0.1514563, "fiftyTwoWeekChangePercent": 121.76137, "earningsTimestamp": 1772112600, "earningsTimestampStart": 1772112600, "earningsTimestampEnd": 1772112600, "earningsCallTimestampStart": 1772112600, "earningsCallTimestampEnd": 1772112600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -3.6, "epsForward": -3.64319, "epsCurrentYear": -3.46598, "priceEpsCurrentYear": -25.216534, "fiftyDayAverageChange": 9.890198, "fiftyDayAverageChangePercent": 0.12759931, "twoHundredDayAverageChange": 32.132526, "twoHundredDayAverageChangePercent": 0.5814003, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-08-21", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "postMarketTime": 1771625376, "regularMarketTime": 1771621202, "exchange": "NGM", "messageBoardId": "finmb_542085131", "exchangeTimezoneName": "America/New_York", "firstTradeDateMilliseconds": 1598016600000, "postMarketChangePercent": 0.0, "postMarketPrice": 87.4, "postMarketChange": 0.0, "regularMarketChange": 0.900002, "regularMarketDayRange": "85.6 - 89.28", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 983401, "marketState": "CLOSED", "displayName": "Kymera Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]